These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20962060)

  • 1. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
    Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
    Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regioselective hydroxylation of omeprazole enantiomers by bacterial CYP102A1 mutants.
    Ryu SH; Park BY; Kim SY; Park SH; Jung HJ; Park M; Park KD; Ahn T; Kang HS; Yun CH
    Drug Metab Dispos; 2014 Sep; 42(9):1493-7. PubMed ID: 25008345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
    Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
    Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regioselective hydroxylation of 17β-estradiol by mutants of CYP102A1 from Bacillus megaterium.
    Cha GS; Ryu SH; Ahn T; Yun CH
    Biotechnol Lett; 2014 Dec; 36(12):2501-6. PubMed ID: 25129047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3.
    Kim DH; Ahn T; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2009 May; 37(5):932-6. PubMed ID: 19237510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of statin drug metabolites through electrochemical and enzymatic oxidations.
    Khera S; Hu N
    Anal Bioanal Chem; 2013 Jul; 405(18):6009-18. PubMed ID: 23760135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
    Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
    Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies.
    Rea V; Kolkman AJ; Vottero E; Stronks EJ; Ampt KA; Honing M; Vermeulen NP; Wijmenga SS; Commandeur JN
    Biochemistry; 2012 Jan; 51(3):750-60. PubMed ID: 22208729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
    Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
    J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
    Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
    Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
    Roitel O; Scrutton NS; Munro AW
    Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regioselective C-H hydroxylation of omeprazole sulfide by Bacillus megaterium CYP102A1 to produce a human metabolite.
    Jang HH; Ryu SH; Le TK; Doan TT; Nguyen TH; Park KD; Yim DE; Kim DH; Kang CK; Ahn T; Kang HS; Yun CH
    Biotechnol Lett; 2017 Jan; 39(1):105-112. PubMed ID: 27640009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
    J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs.
    Kang JY; Ryu SH; Park SH; Cha GS; Kim DH; Kim KH; Hong AW; Ahn T; Pan JG; Joung YH; Kang HS; Yun CH
    Biotechnol Bioeng; 2014 Jul; 111(7):1313-22. PubMed ID: 24474032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes.
    Weber E; Seifert A; Antonovici M; Geinitz C; Pleiss J; Urlacher VB
    Chem Commun (Camb); 2011 Jan; 47(3):944-6. PubMed ID: 21079837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.